1, characteristics of the increasingly tough industry environment API
2003, the U.S. Merck's second largest drugs simvastatin patent expired in the EU, because the sea was completed in 2002 the production processes of the R & D, and with the scale of the production conditions, therefore, when the patent of protection in Europe after the end of the world's few manufacturers have the production conditions, the sea is a large immediate orders, production and sales enjoying explosive growth. With the sea is the benchmark effects, features API industry gradually attracted attention as an industry, and now in China Taizhou, have formed anti-tumor and blood cholesterol, renin-angiotensin-converting enzyme inhibitor drugs in nine categories in the international market, influential on the advantages of bulk drug product. Foreign labor costs, high environmental costs is the industry turning to the internal driving force in developing countries. The early nineties of last century, the bulk of traditional Chinese medicine raw materials, such as dimension C, affords a salt, corticosteroids and other fields to undertake a cost advantage by virtue of the transfer of industry and stimulating the international prices of such raw material medicine down the overall gross interest rates are gradually reduced to 15%; present, including the excellent preparation of domestic manufacturers have also increased the characteristics of both bulk drugs manufacturing (such as Livzon Group, Modern Pharmaceutical (8.5,0.08,0.95%)), while small API enterprises have in enhancing the capacity, resulting in an unprecedented fierce competition in the market. The sea is, for example, we see three years time, statins API from the highest gross margin of 65% to 25% now, the brutal competition in the market makes the characteristics of raw materials tend to shorten the cycle of drug industry, features the final API will be the traditional low-profit bulk drugs? We believe that the story of traditional medicine materials likely to be repeated, continuous appreciation of RMB and the rising costs of environmental protection will accelerate this trend.
2, New Hope road upgrading Profit model, once an industry ripe, then shrinking profit margins may not be far off. API enterprise features more early intervention before the expiration of the patent medicine preparations (to avoid technology research, regulating the market of international demonstration, etc.) and can not reverse the trend of shrinking profit margins, industrial upgrading may be the only way out of difficulties. To India's industrial upgrading, for example, along the bulk API?? Characteristics of bulk drugs?? Generic drugs?? Generic drugs?? Patent drug routes, such as the birth of a new South, Nguyen Thi such a world-class pharmaceutical companies. From upstream to downstream API integration extension agents to improve the industry's voice, and profitability improved significantly. (Value-added raw materials and preparations can be achieved than 1:9 is huge) the outstanding preparation and bulk drugs business enterprises are achieving the same from the opposite direction, extending from the API to the Preparations (Livzon Group, the modern pharmaceutical) or from preparation to the API extensions (Huahaiyaoye (16.44, -0.14, -0.84%), the sea is Pharmaceutical (7.58,0.13,1.74%)), but the real breakthrough is made abroad, international agents occupying high-end market , share the feast of the global market. So far, China has not yet
A pharmaceutical company received FDA agents, national GMP standard in the software difficult to achieve international cGMP standards, including the Sea of South Sichuan China base, Neptune Interlong million doses of influenza vaccine workshop 1000 in accordance with cGMP standards for all construction and FDA is expected to be demonstrated in the near future, we see that the pharmaceutical companies into the pace of internationalization is intense. As a prelude to the international trend, the domestic pharmaceutical enterprises to actively carry out preparations OEM (such as Shanghai Pharmaceutical (13.28,0.32,2.47%), the EU contract, and the sea to cooperate with the elegant, etc.), we believe that with the familiar international market rules and has the FDA, COS demonstrated "different magic weapon" of the business can really take the road of industrial upgrading, the multinational pharmaceutical companies for OEM companies can become a window to understand the international market. I am a professional writer from China Hardware Suppliers, which contains a great deal of information about hd dvd player samsung , headphone with volume control, welcome to visit!
Related Articles -
hd dvd player samsung, headphone with volume control,
|